1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

        <em id="8sgz1"><label id="8sgz1"></label></em>
      2. <em id="8sgz1"><label id="8sgz1"></label></em>
        <em id="8sgz1"></em>
        <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

        <button id="8sgz1"></button>
        west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "心房" 223 results
        • Cryomaze ablation procedure for atrial fibrillation concomitant with valve surgery

          Objective To summarize safety and effectiveness of cryomaze ablation procedure concomitant with valve surgery. Methods We retrospectively investigated the clinical data of 62 patients (24 males and 38 females) with mean age of 49.4±14.2 years who underwent cryomaze ablation procedure concomitant with valve surgery in our hospital from August 2013 through July 2015. The heart rhythm of the patients after surgery was supervised by 12-leads electrical cardiogram respectively. Results The rate of sinus rhythm restored right after surgery was 98.4%. The rate of sinus rhythm restored at the time of discharge was 93.4%. The rate of sinus rhythm restored 3 months, 6 months, 12 months, 18 months after surgery was 90.2%, 87.3%, 85.0%, 83.3% respectively. The one-year post-operation rate of sinus rhythm restored for the group of right minimal invasive thoracoscopic assisted mitral valve surgery was 90.5%. Longer duration for atrial fibrillation (>7 years) was a risk factor for the reoccurrence of atrial fibrillation 1 year after surgery (P<0.05). Conclusion Cryomaze ablation procedure concomitant with valve surgery is quite effective in treatment of rheumatic valve disease and atrial fibrillation. This approach is associated with fewer complications, comparable atrial fibrillation reoccurrence for short-term follow-up.

          Release date:2017-04-24 03:51 Export PDF Favorites Scan
        • Real-time Three-dimensional Echocardiography (RT-3DE) Application in Evaluation of Left Ventricular Motion in Patients with Rheumatic Mitral Stenosis

          ObjectiveTo evaluate myocardial segmental motion function in left ventricular of patients with rheumatic mitral stenosis by using the technology of real-time three-dimensional echocardiography (RT-3DE). MethodsWe retrospectively analyzed the clinical data of 14 patients with rheumatic mitral stenosis between October and November 2014 in our hospital as a trial group. There were 4 males and 10 females with a mean age of 50.9±9.0 years ranging from 34 to 64 years. We chose 11 healthy individuals as a control group. There were 7 males and 4 females with a mean age of 49.5±9.7 years ranging from 32 to 67 years. Both the two groups were subjected to myocardial performance evaluation using two-dimensional echocardiography (2DE) and real-time three-dimensional echocardiography (RT-3DE) to examine the left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), longitudinal strain, circumferential strain, area strain, and lateral strain of each left ventricular myocardial segments. Result RT-3DE detected that the trial group had significantly lower values of LVEF, LVEDV and LVESV than those of the control group (P < 0.05). RT-3DE also revealed that the trial group had a significantly weaker longitudinal strain than the control group (P < 0.05). ConclusionRT-3DE is an accurate technology for assessing myocardial motion and function in patients with rheumatic mitral valve disease.

          Release date: Export PDF Favorites Scan
        • Developments of ex vivo cardiac electrical mapping and intelligent labeling of atrial fibrillation substrates

          Cardiac three-dimensional electrophysiological labeling technology is the prerequisite and foundation of atrial fibrillation (AF) ablation surgery, and invasive labeling is the current clinical method, but there are many shortcomings such as large trauma, long procedure duration, and low success rate. In recent years, because of its non-invasive and convenient characteristics, ex vivo labeling has become a new direction for the development of electrophysiological labeling technology. With the rapid development of computer hardware and software as well as the accumulation of clinical database, the application of deep learning technology in electrocardiogram (ECG) data is becoming more extensive and has made great progress, which provides new ideas for the research of ex vivo cardiac mapping and intelligent labeling of AF substrates. This paper reviewed the research progress in the fields of ECG forward problem, ECG inverse problem, and the application of deep learning in AF labeling, discussed the problems of ex vivo intelligent labeling of AF substrates and the possible approaches to solve them, prospected the challenges and future directions for ex vivo cardiac electrophysiology labeling.

          Release date:2024-04-24 09:40 Export PDF Favorites Scan
        • A Meta-analysis on Randomized Controlled Trials of Statins to Prevent Atrial Fibrillation

          Objective To synthesize the available evidence on the efficacy of using statins in the prevention of recurrent and new-onset atrial fibrillation (AF). Methods We searched PubMed, EMbase, EMB Reviews-Cochrane Central Register of Controlled Trials (Issue 3, 2007), CBMdisc, VIP, and CNKI databases from establishment to 15th Sep. 2007 to identify randomized controlled trials (RCTs) covering the use of statins for the patients with persistent AF after electrical cardioversion, paroxysmal and postoperative AF. Meta-analysis was performed using RevMan 4.3 software after the strict evaluation of the methodological quality of the included RCTs. Results Five RCTs including 470 patients were included. Significant heterogeneity was found when the data were pooled, so a random effect model was used for metaanalysis. Compared with placebo or no use of statins, the statins decreased risk of AF recurrence and postoperative AF (RR=0.61, 95%CI 0.43 to 0.88, P=0.008). Sensitivity analysis showed that the result was stable. The fail-safe number was 52.91. Conclusion The statins may decrease incidence of AF recurrence and postoperative AF. Because of the low quality and the small number of included studies, larger sample-size, randomized, double-blinded controlled trials are needed.

          Release date:2016-09-07 02:09 Export PDF Favorites Scan
        • Early and mid-term outcomes of total thoracoscopic Box Lesion radiofrequency ablation in patients with atrial fibrillation

          ObjectiveTo evaluate the early and mid-term outcomes of total thoracoscopic Box Lesion radiofrequency ablation in patients with atrial fibrillation.MethodsThe clinical data of 31 patients with atrial fibrillation who underwent total thoracoscopic Box Lesion radiofrequency ablation between November 2011 and March 2018 at the Department of Cardiac Surgery in our hospital were retrospectively analyzed, including 23 males and 8 females at an average age of 66.17±8.32 years. All patients did not have concomitant severe organic heart disease which required surgical intervention.ResultsThere were 20 patients with paroxysmal atrial fibrillation, 8 with persistent atrial fibrillation, and 3 with long-standing persistent atrial fibrillation. Twenty-nine patients got the 3-year follow-up, and 2 patients were lost to the follow-up 6 months after the surgery. The procedure was successfully performed in all patients, with an average operation time of 113.00±26.00 min. There was no perioperative death or related complication. All patients were restored to sinus rhythm immediately after surgery. Five patients got atrial fibrillation during postoperative hospitalization, which reverted to sinus rhythm after electrical cardioversion. The rate of sinus rhythm maintenance was 62.9%, 55.9% and 52.4% in postoperative 1, 2 and 3 years, respectively. No patient died during the period, and no procedure-related complication was observed.ConclusionTotal thoracoscopic Box Lesion radiofrequency ablation effectively shortens operation time, and reduces surgical trauma and procedure-related complications, meanwhile, ensures the surgical outcomes.

          Release date:2021-09-18 02:21 Export PDF Favorites Scan
        • 改良沖洗式雙極射頻消融手術治療心房顫動

          目的 分析心瓣膜置換術中同期行改良沖洗式雙極射頻消融治療心房顫動的臨床效果。 方法 回顧性分析2009年4月至2011年6月安徽醫科大學第二附屬醫院心瓣膜病合并心房顫動34例患者在體外循環下行心瓣膜置換術+改良沖洗式雙極射頻消融手術的臨床資料,其中男21例,女13例;年齡41~76 (50.5±11.3)歲。風濕性心臟瓣膜病31例,心瓣膜退行性病變3例;合并慢性持續性/永久性心房顫動27例,陣發性心房顫動7例。均采用Medtronic Cardioblate 68000沖洗式雙極射頻消融系統進行消融操作。消融手術包括雙側肺靜脈的環形隔離、左心耳切除、左右心房消融(改良Cox-mazeⅢ手術路徑)和Marshall韌帶切除。術后常規予胺碘酮治療。 結果 全組無死亡,除2例術后并發Ⅲ○房室傳導阻滯、安裝永久性心臟起搏器外,其余患者未發生與消融相關的并發癥。術后31例轉為非心房顫動心律(竇性心律25例,結性心律4例,起搏心律2例),3例維持心房顫動心律。隨訪3~20個月,29例維持竇性心律(85.3%),3例心房顫動心律,2例起搏心律。 結論 改良沖洗式雙極射頻消融治療心房顫動安全、有效。

          Release date:2016-08-30 05:50 Export PDF Favorites Scan
        • Factors Determining Left Atrial Reverse Remodeling after Mitral Valve Replacement

          ObjectiveTo observe the changes of left atrial geometry before and after mitral valve replacement in patients with different types of mitral valve disease and different heart rhythm, and to identify factors determining left atrial remodeling after mitral valve replacement. MethodsA total of 215 consecutive patients of mitral valve replacement in Department of Thoracic and Cardiovascular Surgery of West China Hospital, Sichuan University from January 2003 to March 2008 were selected and followed up for this study. There were 52 male and 163 female patients with their age of 40.58±10.54 years (ranged, 18-67 years). St. Jude Medical mechanical valves were used. According to the type of mitral valve diseases (mitral stenosis (MS) or mitral regurgitation (MR)) and heart rhythm (atrial fibrillation (AF) or sinus rhythm (SR)), patients were divided into 4 groups. There were 54 patients with MS and SR (including 13 male and 41 female patients with their age of 39.31±9.46 years), 56 patients with MS and AF (including 14 male and 42 female patients with their age of 41.12±10.72 years), 52 patients with MR and SR (including 12 male and 40 female patients with their age of 39.71±10.09 years), 53 patients with MR and AF (including 13 male and 40 female patients with their age of 40.19±11.87 years). All patients had routine examinations and echocardiogram preoperatively and two years after surgery. Left atrial anteroposterior diameter (LAD), left atrial area (LAA), left atrial volume (LAV) and left atrial volume index (LAVi) were used to analyze the changes of left atrial geometry. ResultsThere was no in-hospital death. Major postoperative complications included low cardiac output syndrome in 5 patients, pneumonia in 6 patients. LAVi were lower in mitral stenosis patients than that in mitral regurgitation patients (P<0.05), LAVi were lower in patients with sinus rhythm than that in patients with atrial fibrillation (P<0.05). Two years after mitral valve replacement, the extent of left atrial reverse remodeling were significantly greater in mitral regurgitation patients than in mitral stenosis patients (P<0.05), and the extent of left atrial reverse remodeling were significantly greater in patients with sinus rhythm than that in patients with atrial fibrillation (P<0.05). ConclusionsAge, atrial fibrillation, preoperative left atrial volume, mitral regurgitation, left ventricle end-diastolic diameter are important influencing factors of left atrial reverse remodeling after mitral valve replacement.

          Release date: Export PDF Favorites Scan
        • Changes of Thyroid Hormone Receptor Activity in Patients with Hypertensive Non-valvular Atrial Fibrillation

          目的 研究高血壓非瓣膜心房顫動患者甲狀腺激素受體(TR)的活性差異,以探討此類患者心房顫動發生發展的可能機制。 方法 2008年1月-2010年1月序貫收集103例高血壓非瓣膜心房顫動患者的相關資料(48例陣發性心房顫動、55例持續性心房顫動),并收集50例單純高血壓患者。收集各組患者的相關人口學數據及檢查結果,并采用放射性分析技術測定各組患者外周血淋巴細胞及淋巴細胞核TR的活性,主要包括平衡解離常數(Kd)及最大結合容量(MBC)。 結果 心房顫動患者淋巴細胞TR的Kd較單純高血壓患者小(越小表示與甲狀腺激素的親和力越高),且持續性心房顫動患者的Kd較陣發性心房顫動患者更小(0.77 ± 0.43、1.02 ± 0.41,P<0.001);心房顫動患者淋巴細胞TR的MBC較單純高血壓患者小(越小表示受體總量越少),且持續性心房顫動患者TR的MBC較陣發性心房顫動患者更小(36.10 ± 12.40、65.22 ± 30.90,P<0.001)。淋巴細胞核TR的Kd及MBC也存在類似情況。簡單相關分析提示左房直徑與淋巴細胞TR的Kd及MBC呈負相關,另外,調整相關指標后偏相關分析也提示左房直徑與Kd及MBC呈負相關(Kd:r=?0.296,MBC:r=?0.448;P均<0.01);淋巴細胞核TR的Kd及MBC也存在類似情況。 結論 高血壓非瓣膜心房顫動患者中,TR的總量減少,并且持續心房顫動組低于陣發心房顫動組;甲狀腺激素與受體的親和力在心房顫動患者中升高,且持續心房顫動組高于陣發心房顫動組。另外,還發現TR的Kd和MBC與左房直徑均呈負相關。這些改變可能是高血壓非瓣膜心房顫動患者心房顫動發生及維持的一種重要機制。

          Release date:2016-09-08 09:13 Export PDF Favorites Scan
        • 侵犯心臟大血管局部晚期肺癌的外科治療

          摘要: 目的 總結侵犯大血管和左心房的局部晚期非小細胞肺癌的外科治療經驗。 方法 回顧性分析我科2005年2月至2009年11月期間對32例局部晚期(T4N0M0、T4N1M0、T4N2M0)非小細胞肺癌患者(男27例,女5例;年齡48~73歲,中位年齡58歲)采用原發腫瘤加部分心房或大血管切除治療的臨床資料。侵犯上腔靜脈和無名靜脈5例,肺動脈干4例,左心房23例。行左全肺及左心房部分切除13例,左全肺及肺動脈干部分切除4例,右全肺及左心房部分切除9例(其中2例在體外循環輔助下進行),右肺中下葉及部分左心房切除1例,右肺上葉及上腔靜脈部分切除人工血管置換3例,上腔靜脈修補2例。 結果 本組32例患者無手術死亡,手術完全切除16例。術后僅有3例發生心律失常。 腫瘤病理類型:鱗癌25例,腺癌5例,大細胞癌2例。術后pTNM分期:T4N0M03例,T4N1M0 11例,T4N2M0 18例。所有患者術后隨訪6個月~5年,中位生存時間15個月;T4N0 M0、T4N1M0患者的中位生存時間為19個月,T4N2M0患者的中位生存時間為10個月。1例患者無瘤生存5年。 結論 侵及心房大血管的局部晚期肺癌(Ⅲb期)采用擴大切除術能提高根治性手術切除率,改善患者生活質量,提高局部晚期肺癌患者的生存率。

          Release date:2016-08-30 06:02 Export PDF Favorites Scan
        • Different doses of metoprolol in preventing new-onset atrial fibrillation after coronary artery bypass graft: A randomized controlled trial

          ObjectiveTo analyze different doses of metoprolol in prevention of atrial fibrillation (AF) after coronary artery bypass graft (CABG).MethodsFrom June 2016 to August 2017, 358 patients undergoing CABG in cardiothoracic surgery in Nanjing First Hospital were randomly divided into two groups according to the dose of metoprolol: a group A with metoprolol of 25 mg/d, a total of 182 patients, including 145 males and 37 females, with an average age of 65.40±10.52 years; a group B with metoprolol of 75 mg/d, a total of 176 patients, 138 males and 38 females with an average age of 63.31±9.04 years. The incidence of AF was observed 5 days after surgery.ResultsThe incidence of post-CABG AF (PCAF) in the group A and the group B was 27.47%, 18.18%, respectively with a statistical difference (P=0.04). PCAF was detected its maximum peak on the second day post-surgery. Of patients at age of 70 years or more, the incidence of PCAF in the group A was higher than that in the group B with no statistical difference (P=0.18). Among the patients with left ventricular ejection fraction (LVEF) lower than 40%, there was no statistical difference in the incidence of PCAF between the two groups (P=0.76).ConclusionMetoprolol 75.00 mg/d is better than 25.00 mg/d in preventing new AF after CABG.

          Release date:2019-05-28 09:28 Export PDF Favorites Scan
        23 pages Previous 1 2 3 ... 23 Next

        Format

        Content

          1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

            <em id="8sgz1"><label id="8sgz1"></label></em>
          2. <em id="8sgz1"><label id="8sgz1"></label></em>
            <em id="8sgz1"></em>
            <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

            <button id="8sgz1"></button>
            欧美人与性动交α欧美精品